Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intense Aflibercept Regimen for Refractory nvAMD
NCT03594461Phase 2Unknown
- Sponsor
- Vitreous Retina Macula Consultants of New York
- Start
- Sep 2018
- Primary completion
- Mar 2020
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in neovascular age-related macular degeneration (NVAMD), sponsored by Vitreous Retina Macula Consultants of New York. Status: unknown.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03594461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03594461.